Probi publishes annual report for 2016

This information was submitted for disclosure on 31 March 2017 at 08.30 (cet).

Probi's Annual Report for 2016 is now available on the company website, www.probi.com under Investors / Financial Reports / Annual Reports. Distribution of the printed annual report will start during week 15 to shareholders who subscribe to our financial reporting.

This information is information that Probi AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 8.30 CET on 31 March 2017.

FOR FURTHER INFORMATION, CONTACT:
Peter Nählstedt, CEO, Probi, tel +46 46 286 89 23, e-mail: peter.nahlstedt@probi.se
Niklas Brandt, CIO, Probi, tel +46 46 286 89 26, e-mail: niklas.brandt@probi.se

ABOUT PROBI
Probi AB is a Swedish publicly traded bioengineering company that develops effective and well-documented probiotics. Through its world-leading research, Probi has created a strong product portfolio in the gastrointestinal health and immune system niches. Probi’s products are available to consumers in more than 30 countries worldwide. Probi’s customers are leading food, health-product and pharmaceutical companies in the Functional Food and Consumer Healthcare segments. In 2016, Probi generated sales of MSEK 444. Probi’s shares are listed on Nasdaq Stockholm, Mid Cap. Probi has about 4,700 shareholders. For more information, please visit www.probi.se.

Tags:

About Us

Probi AB is a Swedish publicly traded biotechnology company that develops effective and well-documented probiotics. Through its research, Probi has created a strong product portfolio in the gastrointestinal health and immune system areas. The products are available to consumers in more than 40 countries worldwide. The customers are leading food, health-product and pharmaceutical companies in the Functional Food and Consumer Healthcare segments. The Probi share is listed on NASDAQ OMX Stockholm, Mid-cap. Read more on www.probi.se.

Subscribe

Documents & Links